Alle verbonden artikelen

Clinical development of new formulations of cytotoxics in solid tumors.

Auteurs : Azim HA, Awada A
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pagina's : 325-31

Význam biomarkerù v klinické onkologii

Auteurs : Klastersky J
Jaar : 2012
Journal : lekarsky Sbornik
Volume : sup1
Pagina's : 14-17

Percutaneous endoscopic jejunostomy in patients with gastroparesis following lung transplantation: feasibility and clinical outcome.

Auteurs : Toussaint E, Van Gossum A, Ballarin A, Le Moine O, Estenne M, Knoop C, Devière J, Arvanitakis M
Jaar : 2012
Journal : Endoscopy
Volume : 44(8)
Pagina's : 772-5

Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology.

Auteurs : Awada A, Vandone AM, Aftimos P
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pagina's : 297-304

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.

Auteurs : Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, de Azambuja E, Piccart-Gebhart M
Jaar : 2012
Journal : Ann Oncol
Volume : 23(4)
Pagina's : 853-859

Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer - Authors' reply.

Auteurs : Baselga J, de Azambuja E, Bradbury I, Gelber R
Jaar : 2012
Journal : Lancet
Volume : 379 (9833)
Pagina's : 2238

Esophageal self-expanding metallic stent (SEMS) migration: it's a topsy-turvy world.

Auteurs : Toussaint E, Zalcman M, Devière J, Le Moine O, Arvanitakis M
Jaar : 2012
Journal : Endoscopy
Volume : 44 Suppl 2
Pagina's : E352-3

New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

Auteurs : Awada A, Bozovic-Spasojevic I, Chow L
Jaar : 2012
Journal : Cancer Treat Rev
Volume : 38(5)
Pagina's : 494-504

Clinical trial design in head and neck cancer: from past experiences to future perspectives.

Auteurs : de Castro G Jr, Henrique dos Anjos C, Lalami Y, Awada A
Jaar : 2012
Journal : Clinical Investigation
Volume : 2(5)
Pagina's : 473-481

Minimal residual disease and circulating tumor cells in breast cancer: open questions for research.

Auteurs : Ignatiadis M, Sotiriou C, Pantel K
Jaar : 2012
Journal : Recent Results Cancer Res.
Volume : 195
Pagina's : 3-9

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Auteurs : Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart-Gebhart M, Harbeck N
Jaar : 2012
Journal : Breast Cancer Res. Treat.
Volume : 134(3)
Pagina's : 1149-59

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.

Auteurs : Berghmans T, Remmelink M, Awada A
Jaar : 2012
Journal : Lung Cancer : Targets and Therapy
Volume : 3
Pagina's : 91-99

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

Auteurs : Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G
Jaar : 2012
Journal : Breast
Volume : 21(1)
Pagina's : 20-6

Understanding the biology of triple-negative breast cancer.

Auteurs : Criscitiello C, Azim HA, Schouten PC, Linn SC, Sotiriou C
Jaar : 2012
Journal : Ann Oncol
Volume : 23 Suppl 6
Pagina's : vi13-vi18

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.

Auteurs : Bergh J, Mariani G, Cardoso F, Liljegren A, Awada A, Viganò L, Huang X, Verkh L, Kern KA, Giorgetti C, Gianni L
Jaar : 2012
Journal : Breast
Volume : 21(4)
Pagina's : 507-13

Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.

Auteurs : Azim H, Azim HA
Jaar : 2012
Journal : Future Oncol
Volume : 8(2)
Pagina's : 135-44

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Auteurs : Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ
Jaar : 2012
Journal : Lancet Oncol
Volume : 13(9)
Pagina's : 897-905

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.

Auteurs : Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber Rd, Bernhard J, + collaborators (among others :, Nogaret JM
Jaar : 2012
Journal : Br J Cancer
Volume : 106(10)
Pagina's : 1618-25

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

Auteurs : Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart-Gebhart M
Jaar : 2012
Journal : Lancet Oncol
Volume : 13(6)
Pagina's : e240-8

Liquid biopsy to test new treatment strategies in breast cancer: are we there yet?

Auteurs : Ignatiadis M, Piccart-Gebhart M
Jaar : 2012
Journal : Ann Oncol
Volume : 23(7)
Pagina's : 1653-5